Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Capital Expenditures (2016 - 2025)

Tg Therapeutics has reported Capital Expenditures over the past 9 years, most recently at $67000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $67000.0 for Q4 2025, up 219.05% from a year ago — trailing twelve months through Dec 2025 was $214000.0 (up 375.56% YoY), and the annual figure for FY2025 was $214000.0, up 375.56%.
  • Capital Expenditures for Q4 2025 was $67000.0 at Tg Therapeutics, down from $80000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for TGTX hit a ceiling of $175000.0 in Q2 2021 and a floor of $3000.0 in Q4 2022.
  • Median Capital Expenditures over the past 4 years was $42000.0 (2025), compared with a mean of $51846.2.
  • Biggest five-year swings in Capital Expenditures: soared 288.89% in 2021 and later crashed 96.25% in 2022.
  • Tg Therapeutics' Capital Expenditures stood at $80000.0 in 2021, then crashed by 96.25% to $3000.0 in 2022, then skyrocketed by 600.0% to $21000.0 in 2024, then soared by 219.05% to $67000.0 in 2025.
  • The last three reported values for Capital Expenditures were $67000.0 (Q4 2025), $80000.0 (Q3 2025), and $42000.0 (Q2 2025) per Business Quant data.